Myelodysplastic syndromes

What is Myelodysplastic syndromes?

Myelodysplastic syndromes (MDS) are a group of rare blood cancers that occur when the bone marrow fails to produce healthy, mature blood cells. Instead of functioning normally, the bone marrow produces abnormal, immature cells that cannot carry out their intended roles in the body. MDS primarily affects older adults, with the highest incidence occurring in people over 70 years of age. The condition affects approximately 4 out of every 100,000 people, making it a rare but significant hematologic disorder that can severely impact quality of life and may progress to acute leukemia.

Key statistics

Symptoms

Common symptoms: Fatigue, weakness, shortness of breath, pale skin, frequent infections, easy bruising, bleeding, dizziness, heart palpitations.

The symptoms of MDS primarily result from cytopenias—low counts of healthy blood cells. Early symptoms often include persistent fatigue and weakness due to anemia (low red blood cell count), which may be accompanied by shortness of breath during normal activities and pale skin or nail beds. Common symptoms also include frequent or severe infections due to low white blood cell counts (neutropenia), and easy bruising, nosebleeds, or prolonged bleeding from minor cuts due to low platelet counts (thrombocytopenia). Serious symptoms may include severe bleeding episodes, life-threatening infections, or symptoms related to severe anemia such as chest pain or heart failure. Many patients require regular blood transfusions, leading to potential iron overload complications over time.

Causes and risk factors

MDS is an acquired clonal disorder, meaning it develops when genetic mutations occur in blood stem cells during a person’s lifetime rather than being inherited from parents. The exact cause of these mutations is often unknown, but several risk factors have been identified. Previous cancer treatment with chemotherapy or radiation therapy significantly increases the risk of developing treatment-related MDS, typically 2-8 years after exposure. Environmental factors including prolonged exposure to benzene, heavy metals, or certain pesticides may contribute to risk. Smoking tobacco doubles the risk of developing MDS. Pre-existing blood disorders, certain genetic syndromes like Down syndrome, and advanced age are additional risk factors. Most cases of MDS are considered “de novo,” meaning they arise without an identifiable cause.

Submit Your Paper

Prevention

Currently, there are no established methods for preventing MDS, as most cases arise spontaneously without known environmental triggers. Since MDS is an acquired condition rather than inherited, genetic testing and carrier screening are not applicable for prevention purposes. However, reducing exposure to known risk factors may help lower the overall risk. This includes avoiding unnecessary radiation exposure, limiting contact with benzene and other harmful chemicals, not smoking tobacco, and following occupational safety guidelines when working with potentially carcinogenic substances. For patients who have received cancer treatment, regular monitoring by healthcare providers may help with early detection, though this does not prevent the condition from developing.

Complications

Without treatment, MDS typically progresses and can lead to several serious complications. The most significant risk is transformation to acute myeloid leukemia (AML), which occurs in approximately 30% of patients and carries a much worse prognosis. Severe cytopenias can result in life-threatening bleeding due to extremely low platelet counts, overwhelming infections due to insufficient white blood cells, and severe anemia requiring frequent blood transfusions. Chronic transfusion dependence leads to iron overload, which can damage the heart, liver, and endocrine organs. Progressive bone marrow failure may eventually become incompatible with life. The overall quality of life deteriorates significantly due to persistent fatigue, increased susceptibility to infections, and the burden of frequent medical interventions.

Diagnosis

Diagnosing MDS requires a comprehensive evaluation including blood tests and bone marrow examination. Initial blood work typically reveals cytopenias affecting one or more cell lines, often with characteristic morphologic abnormalities visible under microscopy. A bone marrow biopsy and aspiration are essential for definitive diagnosis, showing dysplastic changes in developing blood cells and typically less than 20% blasts (which distinguishes MDS from acute leukemia). Cytogenetic analysis examines chromosomal abnormalities, while flow cytometry can identify abnormal cell surface markers. Molecular genetic testing may reveal specific mutations in genes such as SF3B1, SRSF2, or TP53. Additional tests include serum erythropoietin levels, vitamin B12 and folate levels to exclude nutritional deficiencies, and iron studies. The World Health Organization classification system helps categorize MDS subtypes based on morphology, cytogenetics, and blast percentage.

Treatment

Treatment approaches for MDS depend on the patient’s age, overall health, disease subtype, and risk stratification. Lower-risk patients may receive supportive care including blood transfusions, growth factor support with erythropoiesis-stimulating agents, and iron chelation therapy to manage transfusion-related iron overload. Hypomethylating agents like azacitidine and decitabine are first-line treatments for higher-risk MDS and can improve survival and delay leukemic transformation. Lenalidomide is particularly effective for patients with deletion 5q chromosome abnormalities. Luspatercept, a newer agent, helps reduce transfusion requirements in certain patients with lower-risk MDS. For younger, fit patients with higher-risk disease, allogeneic hematopoietic stem cell transplantation remains the only potentially curative treatment option. Investigational therapies and clinical trials may offer additional options for appropriate candidates.

Prognosis

The prognosis for MDS varies significantly based on several factors including age, cytogenetic abnormalities, bone marrow blast percentage, and degree of cytopenias. Risk stratification systems like the Revised International Prognostic Scoring System (IPSS-R) help predict outcomes. Lower-risk patients may have a median survival of 5-8 years, while higher-risk patients may survive only 1-2 years without treatment. With appropriate treatment, including hypomethylating agents, median survival can be extended by 6-12 months or more. Patients who undergo successful stem cell transplantation may achieve long-term remission, with 5-year survival rates of 40-60% depending on age and disease characteristics. Quality of life often improves with effective treatment, particularly when transfusion dependence is reduced and infections become less frequent.

Quality of life

Living with MDS requires significant lifestyle adaptations and ongoing medical management. Patients should maintain a balanced, nutritious diet and stay well-hydrated, while avoiding raw or undercooked foods that might increase infection risk. Gentle, regular exercise as tolerated can help maintain strength and energy levels, though activities should be modified based on current blood counts and energy levels. Adequate sleep and stress management are crucial for overall well-being. Patients with low blood counts should take precautions to avoid infections, including frequent handwashing, avoiding crowded places during illness outbreaks, and seeking prompt medical attention for any signs of infection. Mental health support is important, as living with a chronic blood cancer can cause anxiety and depression. Many patients benefit from support groups and counseling to help cope with the emotional aspects of their diagnosis.

Pregnancy and fertility

MDS primarily affects older adults, so pregnancy considerations are less common but important to address for younger patients. The disease and its treatments can significantly impact fertility in both men and women. Many MDS treatments, including chemotherapy agents and stem cell transplantation, can cause infertility. For patients of reproductive age considering treatment, fertility preservation options such as egg or sperm banking should be discussed before starting therapy. Pregnancy in women with active MDS is generally not recommended due to the risks posed by low blood counts and the potential need for treatments that could harm the developing fetus. Genetic counseling may be beneficial, though MDS is typically not inherited.

Children

While MDS is predominantly a disease of older adults, pediatric MDS does occur and represents less than 5% of all cases. Childhood MDS often has different underlying causes, including inherited bone marrow failure syndromes, previous cancer treatments, or genetic predispositions such as Down syndrome or Fanconi anemia. The diagnosis and treatment approach in children may differ from adult protocols, with greater emphasis on stem cell transplantation as a curative option when appropriate donors are available. Pediatric patients generally have better tolerance for intensive treatments, but long-term follow-up is crucial to monitor for treatment-related complications and ensure proper growth and development.

When to see a doctor

Immediate medical attention is needed for signs of serious bleeding (such as severe nosebleeds, vomiting blood, or unusual bruising), high fever above 100.4°F (38°C), severe shortness of breath, chest pain, or signs of severe infection. Routine medical care should be sought for persistent fatigue lasting more than a few weeks, frequent infections, easy bruising, pale skin, dizziness, or heart palpitations. Patients with known MDS should follow their prescribed monitoring schedule and contact their healthcare team if they experience worsening symptoms, new concerning signs, or have questions about their condition. Regular blood count monitoring is essential for managing the disease and adjusting treatments as needed.

Regional context

Limited specific data exists regarding MDS prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and broader Eastern Mediterranean area. The condition likely affects these populations at rates similar to global estimates, with environmental and genetic factors potentially influencing regional variations. Access to specialized hematologic care and advanced treatments may vary across different healthcare systems in these regions. Healthcare providers and researchers in these areas are encouraged to contribute data and clinical experiences to the Global Medical Journal to help build a more comprehensive understanding of MDS patterns and outcomes in these populations.

Research and clinical trials

Current MDS research focuses on developing more effective treatments, understanding disease mechanisms, and improving patient outcomes. Promising areas include novel hypomethylating agents, combination therapies, immunotherapies, and targeted treatments based on specific genetic mutations. Research into biomarkers for predicting treatment response and disease progression is ongoing. Recent breakthroughs include the approval of luspatercept and continued investigation of venetoclax combinations. Clinical trials are examining new drug combinations, cellular therapies, and strategies to overcome treatment resistance. Patients and caregivers can search for relevant clinical trials at ClinicalTrials.gov using terms like “myelodysplastic syndrome” to find potentially suitable research opportunities.

Frequently asked questions

Is MDS a type of cancer?

Yes, MDS is classified as a blood cancer or hematologic malignancy. It affects the bone marrow’s ability to produce healthy blood cells and can potentially transform into acute leukemia.

How is MDS different from leukemia?

MDS typically has fewer immature blast cells in the bone marrow (less than 20%) compared to acute leukemia (20% or more). MDS also primarily causes problems with blood cell quality and quantity rather than the rapid cell proliferation seen in acute leukemia.

Will I need blood transfusions forever?

Not necessarily. While many MDS patients require transfusions initially, effective treatments like hypomethylating agents or luspatercept may reduce or eliminate transfusion dependence in some patients.

Can MDS be cured?

Currently, stem cell transplantation is the only potentially curative treatment for MDS, though it’s not suitable for all patients due to age or health considerations. Other treatments can significantly improve quality of life and extend survival.

Is MDS hereditary?

Most cases of MDS are acquired during a person’s lifetime and are not inherited. However, rare hereditary syndromes can predispose individuals to developing MDS, particularly in younger patients.

Support and resources

MDS Foundation – Comprehensive support and information for patients and families
Website: mds-foundation.org

National Organization for Rare Disorders (NORD)
Website: rarediseases.org

Orphanet – European reference portal for rare diseases
Website: orpha.net

Leukemia & Lymphoma Society
Website: lls.org

European Organisation for Rare Diseases (EURORDIS)
Website: eurordis.org

ClinicalTrials.gov – Database of clinical studies
Website: clinicaltrials.gov

Related conditions

Acute myeloid leukemia – Can develop as MDS progresses
Aplastic anemia – Another bone marrow failure syndrome
Myelofibrosis – Related myeloid malignancy
Chronic myeloid leukemia – Another type of blood cancer
Paroxysmal nocturnal hemoglobinuria – Can coexist with MDS

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.